SAR447971 / Sanofi, Kymera Therap - LARVOL DELTA

SAR447971 First-in-human Study (clinicaltrials.gov) - P1 | N=114 | Recruiting | Sponsor: Sanofi

First-in-human • New P1 trial • Dermatology • Hidradenitis Suppurativa • Immunology

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration (GlobeNewswire) - "The Phase 1 trial (NCT07629336) is being conducted by the Company’s partner Sanofi. Under the terms of the collaboration, dosing of the first participant triggered a $20 million milestone payment to Kymera from Sanofi...Per the collaboration, Sanofi is leading development, regulatory, and commercial efforts for the program. Kymera is eligible to receive up to $975 million of potential clinical, regulatory and commercial milestones related to KT-485."

Financing • First-in-human • Trial status • Hidradenitis Suppurativa

SAD20411-MAD20412: SAR447971 first-in-human study (clinicaltrialsregister.eu) - P1 | N=134 | Not yet recruiting | Sponsor: Sanofi-Aventis Recherche & Developpement

First-in-human • New P1 trial

KT-485/SAR447971, a selective, potent, oral IRAK4 degrader being advanced in partnership with Sanofi, has the potential to offer a novel oral approach for a variety of chronic immuno-inflammatory diseases. (GlobeNewswire) - "The program has completed IND-enabling studies, with clinical entry expected in 2026."

New trial • Asthma • Atopic Dermatitis • Hidradenitis Suppurativa • Immunology • Inflammatory Bowel Disease • Rheumatoid Arthritis

Kymera Therapeutics Outlines Key 2026 Objectives... (The Manila Times) - "Key Upcoming KT-579 Milestones: Initiate the first-in-human Phase 1 healthy volunteer trial in the first quarter of 2026, with data expected to be reported in the second half of 2026...KT-485/SAR447971, a selective, potent, oral IRAK4 degrader, is being advanced in collaboration with Sanofi for immuno-inflammatory diseases, with a Phase 1 clinical trial expected to initiate in 2026....The Company intends to advance at least one new development candidate towards IND for a first-in-class, oral immunology program in 2026."

First-in-human • New P1 trial • P1 data • Pipeline update • Immunology • Inflammation

KT-485/SAR447971, a selective, potent, oral IRAK4 degrader being advanced in partnership with Sanofi for immuno-inflammatory diseases, is in IND-enabling studies, with clinical entry expected in 2026. (GlobeNewswire)

New trial • Immunology

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update (GlobeNewswire) - "Sanofi has informed Kymera that KT-485/SAR447971, an oral, highly potent and selective development candidate targeting IRAK4 for immuno-inflammatory diseases that Kymera has discovered and characterized through preclinical studies, has been selected to advance into clinical studies. Following extensive preclinical work supporting its robust development potential, KT-485 is being prioritized for development under the companies’ existing IRAK4 collaboration, and is expected to advance into Phase 1 testing next year. Based on the planned development of KT-485, Sanofi will not advance KT-474....In conjunction with its plans to advance KT-485, Sanofi also communicated its decision to exercise its participation election right for the IRAK4 target under the terms of the companies’ collaboration agreement. Under the agreement, Kymera achieved a $20 million milestone in the second quarter of 2025 related to preclinical activities associated with KT-485."

New P1 trial • Pipeline update • Immunology • Inflammation